Sivik Global Healthcare Has Trimmed Stake in Vertex Pharmaceuticals Com Stk (VRTX) by $760,000; Concho Resources (CXO) Holder Redwood Investments Boosted Its Position by $1.08 Million

February 17, 2018 - By Adrian Erickson

Redwood Investments Llc increased its stake in Concho Resources Inc. (CXO) by 14.89% based on its latest 2017Q3 regulatory filing with the SEC. Redwood Investments Llc bought 8,245 shares as the company’s stock declined 5.25% while stock markets rallied. The institutional investor held 63,635 shares of the oil & gas production company at the end of 2017Q3, valued at $8.38 million, up from 55,390 at the end of the previous reported quarter. Redwood Investments Llc who had been investing in Concho Resources Inc. for a number of months, seems to be bullish on the $21.62B market cap company. The stock increased 0.33% or $0.48 during the last trading session, reaching $146.52. About 1.04M shares traded. Concho Resources Inc. (NYSE:CXO) has risen 13.53% since February 17, 2017 and is uptrending. It has underperformed by 3.17% the S&P500.

Krishen Sud decreased its stake in Vertex Pharmaceuticals Inc Com Stk (VRTX) by 9.09% based on its latest 2017Q3 regulatory filing with the SEC. Sivik Global Healthcare Llc sold 5,000 shares as the company’s stock rose 33.61% with the market. The hedge fund run by Krishen Sud held 50,000 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $7.60M, down from 55,000 at the end of the previous reported quarter. Sivik Global Healthcare Llc who had been investing in Vertex Pharmaceuticals Inc Com Stk for a number of months, seems to be less bullish one the $40.70B market cap company. The stock decreased 0.14% or $0.22 during the last trading session, reaching $160.72. About 1.00 million shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 45.69% since February 17, 2017 and is uptrending. It has outperformed by 28.99% the S&P500.

Investors sentiment decreased to 0.99 in 2017 Q3. Its down 0.04, from 1.03 in 2017Q2. It dropped, as 43 investors sold CXO shares while 136 reduced holdings. 30 funds opened positions while 147 raised stakes. 137.75 million shares or 1.36% more from 135.90 million shares in 2017Q2 were reported. Federated Invsts Inc Pa holds 0.01% or 14,592 shares in its portfolio. Amica Pension Fund Board Of Trustees reported 0.08% in Concho Resources Inc. (NYSE:CXO). Rafferty Asset Ltd Llc stated it has 10,849 shares. Strategy Asset Managers Limited Com accumulated 21,234 shares. Axiom Ltd Liability Company De reported 278,980 shares. Panagora Asset Mngmt Inc owns 10,372 shares. Frontier Mgmt Com Ltd Llc reported 277,336 shares. Bridgewater LP has invested 0.01% of its portfolio in Concho Resources Inc. (NYSE:CXO). 107,817 are held by Lazard Asset Mngmt Ltd. Lord Abbett And Ltd Com has 0.08% invested in Concho Resources Inc. (NYSE:CXO) for 215,800 shares. Morgan Stanley holds 0.01% or 271,635 shares in its portfolio. Dodge & Cox has 5.66M shares for 0.6% of their portfolio. Texan Mgmt holds 7,630 shares or 0.67% of its portfolio. Janney Montgomery Scott Llc has 4,491 shares for 0.01% of their portfolio. 11.77M were accumulated by Capital.

Redwood Investments Llc, which manages about $756.78 million and $877.14 million US Long portfolio, decreased its stake in Ross Stores Inc. (NASDAQ:ROST) by 35,514 shares to 113,316 shares, valued at $7.32M in 2017Q3, according to the filing. It also reduced its holding in Euronet Worldwide Inc. (NASDAQ:EEFT) by 7,408 shares in the quarter, leaving it with 128,582 shares, and cut its stake in Facebook Inc. Class A (NASDAQ:FB).

Since January 2, 2018, it had 0 buys, and 1 sale for $603,480 activity.

Among 27 analysts covering Concho Resources Inc. (NYSE:CXO), 16 have Buy rating, 0 Sell and 11 Hold. Therefore 59% are positive. Concho Resources Inc. had 108 analyst reports since July 21, 2015 according to SRatingsIntel. Stifel Nicolaus maintained Concho Resources Inc. (NYSE:CXO) rating on Thursday, October 5. Stifel Nicolaus has “Buy” rating and $185.0 target. Citigroup maintained the shares of CXO in report on Friday, July 21 with “Buy” rating. On Friday, December 16 the stock rating was downgraded by Wells Fargo to “Market Perform”. The firm earned “Hold” rating on Tuesday, July 18 by Cowen & Co. The firm has “Overweight” rating by Barclays Capital given on Wednesday, October 11. Morgan Stanley maintained the stock with “Overweight” rating in Wednesday, January 24 report. Stifel Nicolaus maintained Concho Resources Inc. (NYSE:CXO) on Monday, September 12 with “Buy” rating. The rating was initiated by Canaccord Genuity with “Hold” on Tuesday, April 5. The firm has “Outperform” rating by RBC Capital Markets given on Wednesday, February 22. The firm has “Buy” rating given on Thursday, August 11 by Citigroup.

Since August 31, 2017, it had 0 insider purchases, and 37 insider sales for $109.10 million activity. $580,304 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by Chodakewitz Jeffrey. $324,976 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares were sold by Parini Michael. Shares for $7.33 million were sold by Sachdev Amit on Friday, January 19. 4,250 shares were sold by Arbuckle Stuart A, worth $675,750. 2,125 shares were sold by SMITH IAN F, worth $334,232 on Tuesday, January 16. On Tuesday, January 16 the insider ALTSHULER DAVID sold $8.83M.

Among 30 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 26 have Buy rating, 0 Sell and 4 Hold. Therefore 87% are positive. Vertex Pharmaceuticals had 96 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has “Outperform” rating given on Friday, February 5 by Leerink Swann. Stifel Nicolaus maintained the shares of VRTX in report on Friday, September 29 with “Buy” rating. RBC Capital Markets maintained it with “Buy” rating and $200.0 target in Wednesday, January 31 report. Robert W. Baird maintained the shares of VRTX in report on Wednesday, September 6 with “Buy” rating. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has “Buy” rating given on Thursday, February 1 by Leerink Swann. The firm earned “Buy” rating on Wednesday, September 16 by Nomura. The company was initiated on Wednesday, March 1 by Citigroup. As per Thursday, January 26, the company rating was maintained by Stifel Nicolaus. The rating was maintained by Oppenheimer with “Buy” on Thursday, July 27. Maxim Group maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Wednesday, January 31 with “Buy” rating.

Investors sentiment increased to 1.62 in 2017 Q3. Its up 0.11, from 1.51 in 2017Q2. It increased, as 32 investors sold VRTX shares while 151 reduced holdings. 79 funds opened positions while 217 raised stakes. 231.42 million shares or 0.04% more from 231.33 million shares in 2017Q2 were reported. New Mexico Educational Retirement Board has 23,200 shares for 0.17% of their portfolio. Cullen Frost Bankers holds 0.01% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 2,347 shares. Covington Mgmt holds 75 shares or 0% of its portfolio. Arizona State Retirement System stated it has 75,469 shares or 0.14% of all its holdings. Moreover, Focused Wealth Management has 0% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 65 shares. Advisor Prtnrs Ltd Com holds 5,051 shares or 0.15% of its portfolio. Perceptive Advisors Llc owns 138,626 shares. Citigroup Inc has 138,351 shares. Sei Investments reported 122,519 shares. Moreover, Jefferies Group Limited Liability Corp has 0.03% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Btim, Massachusetts-based fund reported 2,183 shares. Jacobs Levy Equity Management holds 184,950 shares or 0.55% of its portfolio. Proshare Advisors Lc reported 0.3% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Hartford Invest Management reported 54,063 shares. Moreover, Mufg Americas has 0% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 70 shares.

Sivik Global Healthcare Llc, which manages about $250.21M and $293.92 million US Long portfolio, upped its stake in Boston Scientific Corp Com Stk (NYSE:BSX) by 20,000 shares to 260,000 shares, valued at $7.58M in 2017Q3, according to the filing. It also increased its holding in Varian Med Sys Inc Com Stk (NYSE:VAR) by 16,683 shares in the quarter, for a total of 41,683 shares, and has risen its stake in Bluebird Bio (NASDAQ:BLUE).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: